Treatment outcomes from community-based drug resistant tuberculosis treatment programs: A systematic review and meta-analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Weiss, Pamela ^a   Chen, Wenjia ^b   Cook, Victoria J ^b,c   Johnston, James C ^b,c  

^a ROYAL ROADS UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Community based; Multidrug resistant; Treatment; Tuberculosis

Indexed keywords

ARTICLE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OUTPATIENT; POPULATION RESEARCH; PREVALENCE; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; COMMUNITY NETWORKS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84902302062     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-333     Document Type: Article

References (34)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375(9728):1830-1843.
2. World Health Organization Global Tuberculosis Report 2012, Geneva: WHO, World Health Organization.
3. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51(1):6-14.
4. World Health Organization Global Plan to Stop TB 2011-2015 2011, Geneva: WHO, World Health Organization.
5. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005, 9(6):640-645.
6. WHO Guidelines for Programmatic Management of Drug-Resistant Tuberculosis (2011 Update) 2011, Geneva: WHO, WHO.
7. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G, Hopewell PC, Daley CL. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005, 40(7):968-975.
8. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009, 4(9):e7186.
9. Adatu F, Odeke R, Mugenyi M, Gargioni G, McCray E, Schneider E, Maher D. Implementation of the DOTS strategy for tuberculosis control in rural Kiboga District, Uganda, offering patients the option of treatment supervision in the community, 1998-1999. Int J Tuberc Lung Dis 2003, 7(9 Suppl 1):S63-71.
10. Okello D, Floyd K, Adatu F, Odeke R, Gargioni G. Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. Int J Tuberc Lung Dis 2003, 7(9 Suppl 1):S72-79.
11. Wandwalo E, Kapalata N, Egwaga S, Morkve O. Effectiveness of community-based directly observed treatment for tuberculosis in an urban setting in Tanzania: a randomised controlled trial. Int J Tuberc Lung Dis 2004, 8(10):1248-1254.
12. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4(9):e6914.
13. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9(3):153-161.
14. World Health Organization Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis Emergency Update 2008 2008, Geneva: WHO, World Health Organization.
15. Cox D. Analysis of Binary Data 1970, London: Methuen.
16. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, Puri MM, Visalakshi P, Behera D. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009, 13(8):976-981.
17. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, Wares F, Thomas A. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011, 133:529-534.
18. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, Krishnan N, Mohan NS, Sundaram V, Wares F, Narayanan PR. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007, 54(3):117-124.
19. Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, Shin SS, Becerra MC. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006, 117(6):2022-2029.
20. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, Sanchez E, Sarria M, Becerra M, Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348(2):119-128.
21. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Munoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359(6):563-574.
22. Malla P, Kanitz EE, Akhtar M, Falzon D, Feldmann K, Gunneberg C, Jha SS, Maharjan B, Prasai MK, Shrestha B, Verma SC, Zignol M. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 2009, 4(12):e8313.
23. Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M, Lagahid JY, Espinal M, Floyd K. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006, 3(9):e352.
24. Oyieng'o DP, Gardner P, Kisang A, Diero G, Sitienei L, Carter JJ. Community-based treatment of multidrug-resistant tuberculosis: early experience and results from Western Kenya. Public Health Action 2012, 2(2):38-42.
25. Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, Seung KJ. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One 2012, 7(5):e37114.
26. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Coh H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9(8):e1001300.
27. Kangovi S, Mukherjee J, Bohmer R, Fitzmaurice G. A classification and meta-analysis of community-based directly observed therapy programs for tuberculosis treatment in developing countries. J Community Health 2009, 34(6):506-513.
28. Bassili A, Fitzpatrick C, Qadeer E, Fatima R, Floyd K, Jaramillo E. A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. AmJTrop Med Hyg 2013, 89(2):271-280.
29. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001, 5(12):1129-1136.
30. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001, 120(2):343-348.
31. Heller T, Lessells RJ, Wallrauch CG, Barnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010, 14(4):420-426.
32. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. PharmacoEconomics 2012, 30(1):63-80.
33. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012, 7(5):e36966.
34. Cox H, Ford N. Decentralisation of multidrug-resistant-tuberculosis care and management. Lancet Infect Dis 2013, 13(8):644-646.